Fortune 500 announces 2018’s top influential pharma companies
Amassing up to $12.8 trillion in revenues and over a trillion in profits, Fortune 500 has unveiled its top companies which represent up to two-thirds of America’s GDP. We take a look at the top three pharmaceutical companies which made the cut.
Remaining steadfast at #7 position, CVS Health has been a consistent player for over 20 years, amassing revenues of up to $184,765. With over 200,000 employees, the company has undergone significant expansion.
Working to integrate its division Omnicare into community clinics, the company has sought to work to mitigate any risks with regards to escalating healthcare costs, alongside President Trump’s ongoing plans to eradicate Obamacare.
- Alibaba will sell a number of its Tmall Pharmacy units to Alibaba Health Information Technology
- Microsoft partners with Great Ormond Street Hospital, London
- Anthem, Inc is set to acquire palliative care provider Aspire Health
The company announced its decision to acquire health insurer Aetna for a staggering $69bn will see it remain a key leader and remain behind consumer trends.
Ranking down one spot to 6th place, pharmaceutical giant McKesson gained revenues of up to $198,533. A number of mergers and acquisitions at the company has supported its bid to remain a key player in the market, despite ongoing price rises within drug distribution and manufacturing.
Gaining 5th position, United Health have remained steadfast, with profits of $10,558. Its recent deal with Quest Diagnostics and LabCorp will also take the business to new heights and bring a number of value-based programmes to the table.
- Dame Emma Walmsley of GSK breaking healthcare barriersMedical Devices & Pharma
- Merck set to buy Prometheus Biosciences for around $11bnMedical Devices & Pharma
- Johnson & Johnson separates its consumer healthcare businessProcurement & Supply Chain
- Bayer to manufacture CureVac COVID-19 vaccineProcurement & Supply Chain